ES2143238T3 - Derivados de 1-(piperidinil disustituido en posiciones 1,2)-piperazinas sustituidas en posicion 4. - Google Patents

Derivados de 1-(piperidinil disustituido en posiciones 1,2)-piperazinas sustituidas en posicion 4.

Info

Publication number
ES2143238T3
ES2143238T3 ES96937248T ES96937248T ES2143238T3 ES 2143238 T3 ES2143238 T3 ES 2143238T3 ES 96937248 T ES96937248 T ES 96937248T ES 96937248 T ES96937248 T ES 96937248T ES 2143238 T3 ES2143238 T3 ES 2143238T3
Authority
ES
Spain
Prior art keywords
het
alkyl
rent
substituted
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96937248T
Other languages
English (en)
Inventor
Frans Eduard Janssens
Francois Maria Sommen
Dominique Louis Nest Surleraux
Joseph Elisabeth Leenaerts
Roosbroeck Yves Emiel Mari Van
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8220780&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2143238(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Application granted granted Critical
Publication of ES2143238T3 publication Critical patent/ES2143238T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

ESTA INVENCION SE RELACIONA CON COMPUESTOS DE FORMULA (I), LAS FORMAS N-OXIDO, LAS SALES DE ADICION FARMACEUTICAMENTE ACEPTABLES Y SUS FORMAS ESTEROISOMERICAS, EN LAS QUE N ES 0, 1 O 2; M ES 1 O 2, CON TAL QUE, SI M ES 2, ENTONCES N ES 1; P ES 1 O 2; = Q ES = O O = NR 3 ; X ES UN ENLACE COVALENTE O UN RADICAL BIVALENTE DE FORMULA O-, -S-, -NR 3 -; R 1 ES AR 1 , AR 1 , AR 1 C 1-6 ALQUILO O DI(AR 1 )C 1-6 ALQUILO, EN DONDE CADA GRUPO C 16 ALQUILO ES OPCIONALMENTE SUSTITUIDO CON HIDROXI, C 14 ALQUILOXI, OXO O UN SUBSTITUYENTE OXO CETALIZADO; R 2 ES AR 2 , AR SUP,1 C 1-6 ALQUILO, HET 1 O HET 1 C 1-6 ALQ UILO; R 3 ES HIDROGENO O UN ALQUILO C 1-6 ; L ES HIDROGENO; AR 3 ; C 1-6 ALQUILO; C 1-6 ALQUILO SUSTITU IDO CON 1 O 2 SUBSTITUYENTES SELECCIONADOS DE UN GRUPO DE HIDROXI, C 1-6 ALQUILOXI, AR 3 , AR 3 C 1-6 ALQUIL OXI Y HET 2 ; C 36 ALQUENILO; AR 3 C 3-6 ALQUENILO; DI(AR 3 )C 36 ALQUENILO O UN RADICAL DE FORMULA (A-1), (A-2), (A-3), (A-4) O (A-5); AR 1 , AR 2 , AR SUP,3 SON TODOS FENILO O FENILOSUSTITUIDO; HET 1 Y HET S UP,2 SON HETEROCICLOS MONOCICLICOS O BICICLICOS; ESTOS COMPUESTOS SON ANTAGONISTAS DE LA SUSTANCIA P; SE DESCRIBE SU PREPARACION, COMPOSICIONES QUE LOS CONTIENEN Y SU USO COMO MEDICAMENTOS.
ES96937248T 1995-10-30 1996-10-25 Derivados de 1-(piperidinil disustituido en posiciones 1,2)-piperazinas sustituidas en posicion 4. Expired - Lifetime ES2143238T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP95202929 1995-10-30

Publications (1)

Publication Number Publication Date
ES2143238T3 true ES2143238T3 (es) 2000-05-01

Family

ID=8220780

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96937248T Expired - Lifetime ES2143238T3 (es) 1995-10-30 1996-10-25 Derivados de 1-(piperidinil disustituido en posiciones 1,2)-piperazinas sustituidas en posicion 4.

Country Status (31)

Country Link
US (3) US6197772B1 (es)
EP (1) EP0862566B1 (es)
JP (1) JP3073238B2 (es)
KR (1) KR100407067B1 (es)
CN (2) CN1117744C (es)
AR (1) AR004698A1 (es)
AT (1) ATE188691T1 (es)
AU (1) AU704155B2 (es)
BR (1) BR9611184B8 (es)
CA (1) CA2234096C (es)
CY (1) CY2177B1 (es)
CZ (1) CZ291794B6 (es)
DE (1) DE69606196T2 (es)
DK (1) DK0862566T3 (es)
EA (1) EA000909B1 (es)
ES (1) ES2143238T3 (es)
GR (1) GR3033154T3 (es)
HR (1) HRP960507B1 (es)
HU (1) HU227341B1 (es)
IL (1) IL123962A (es)
MX (1) MX9803407A (es)
MY (1) MY116575A (es)
NO (1) NO310232B1 (es)
NZ (1) NZ321575A (es)
PL (1) PL185029B1 (es)
PT (1) PT862566E (es)
SI (1) SI0862566T1 (es)
TR (1) TR199800756T2 (es)
TW (1) TW460473B (es)
WO (1) WO1997016440A1 (es)
ZA (1) ZA969090B (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ321575A (en) * 1995-10-30 1999-05-28 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4- substituted piperazine derivatives
TW429256B (en) * 1995-12-27 2001-04-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-(benzimidazolyl- and imidazopyridinyl)-piperidine derivatives
TW531537B (en) 1995-12-27 2003-05-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives
TW382017B (en) 1995-12-27 2000-02-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-(fused imidazole)-piperidine derivatives
WO1999032486A1 (en) * 1997-12-23 1999-07-01 Alcon Laboratories, Inc. Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
US6391865B1 (en) 1999-05-04 2002-05-21 Schering Corporation Piperazine derivatives useful as CCR5 antagonists
US6689765B2 (en) 1999-05-04 2004-02-10 Schering Corporation Piperazine derivatives useful as CCR5 antagonists
USRE39921E1 (en) 1999-10-07 2007-11-13 Smithkline Beecham Corporation Chemical compounds
GB9923748D0 (en) 1999-10-07 1999-12-08 Glaxo Group Ltd Chemical compounds
AU7788500A (en) * 1999-10-25 2001-05-08 Janssen Pharmaceutica N.V. Use of substance p antagonists for influencing the circadian timing system
GB0025354D0 (en) 2000-10-17 2000-11-29 Glaxo Group Ltd Chemical compounds
DK1373256T3 (da) 2001-03-29 2005-10-10 Schering Corp CCR5-antagonister, der er nyttige til behandling af AIDS
GB0108594D0 (en) * 2001-04-05 2001-05-23 Glaxo Group Ltd Chemical compounds
GB0203022D0 (en) * 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
GB0203020D0 (en) 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
JP2005522436A (ja) * 2002-02-08 2005-07-28 グラクソ　グループ　リミテッド ピペリジルカルボキシアミド誘導体またはそのタキキニン介在疾患の治療における使用
DE60327765D1 (de) 2002-06-24 2009-07-09 Janssen Pharmaceutica Nv Verfahren zur herstellung von n-(2,6-dimethylphenyl)-2-piperazin-1-ylacetamid
WO2004056772A1 (en) * 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Substituted 1,4-di-piperidin-4-yl-piperazine derivatives and their use as tachykinin antagonists
MY141736A (en) * 2002-10-08 2010-06-15 Elanco Animal Health Ireland Substituted 1,4-di-piperidin-4-yi-piperazine derivatives and their use as neurokinin antagonists
EP1551811A1 (en) * 2002-10-17 2005-07-13 Amgen Inc. Benzimidazole derivatives and their use as vanilloid receptor ligands
JO2696B1 (en) 2002-12-23 2013-03-03 شركة جانسين فارماسوتيكا ان. في Derivatives of 1-piperdine-4-yl-4-biprolidine-3-yl-piperazine substituted and used as quinine antagonists
JO2485B1 (en) * 2002-12-23 2009-01-20 شركة جانسين فارماسوتيكا ان. في 1-Piperidine-3-Yl-4-Piperidine-4-Yl-Piperazine derivatives substituted and used as quinine antagonists
AU2003298369B2 (en) 2002-12-23 2009-08-27 Janssen Pharmaceutica N.V. Substituted 4-(4-piperidin-4-yl-piperazin-1-yl)-azepane derivatives and their use as neurokinin antagonists
WO2004056800A1 (en) 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Substituted 1-piperidin-4-yl-4-azetidin-3-yl-piperazine derivatives and their use as neurokinin antagonists
US20060128721A1 (en) * 2003-06-10 2006-06-15 Janssens Frans E Novel formulations of opioid-based treatments of pain comprising substituted 1,4-di-piperidin-4-yl-piperazine derivatives
ES2307025T3 (es) * 2003-06-10 2008-11-16 Janssen Pharmaceutica Nv Combinacion de opioides y un derivado de la piperazina para el tratamiento del dolor.
AR047759A1 (es) * 2003-09-26 2006-02-22 Vertex Pharma Derivados de fenil - piperazina como moduladores de receptores muscarnicos
JO2676B1 (en) * 2004-04-06 2012-06-17 جانسين فارماسوتيكا ان. في Derivatives of second-aza-spiro- (5,4) -dikan and their use as antihistamines
JO2527B1 (en) * 2004-04-06 2010-03-17 شركة جانسين فارماسوتيكا ان. في Derivatives of second-aza-Spiro- (5,5) -andecan and their use as antihistamines
JO2525B1 (en) * 2004-04-08 2010-03-17 شركة جانسين فارماسوتيكا ان. في Derived 4-alkyl-and-4-canoelperidine derivatives and their use as anti-neroquin
WO2005101838A2 (en) 2004-04-13 2005-10-27 Incyte Corporation Piperazinylpiperidine derivatives as chemokine receptor antagonists
WO2005123081A2 (en) * 2004-06-22 2005-12-29 Janssen Pharmaceutica N.V. (2-benzyl-4-{4-[1-(tetrahydrofuran-3-carbonyl)-pyrrolidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-(3,5-trifluoromethyl-phenyl))-methanone for the treatment of schizophrenia
US20060024481A1 (en) * 2004-07-29 2006-02-02 Eastman Kodak Company Jet printing of patterned metal
WO2006023431A2 (en) 2004-08-19 2006-03-02 Monsanto Technology Llc Glyphosate salt herbicidal composition
US7635698B2 (en) * 2004-12-29 2009-12-22 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
EA014239B1 (ru) 2005-03-08 2010-10-29 Янссен Фармацевтика Н.В. Производные диаза-спиро-[4,4]нонана в качестве антагонистов нейрокинина (nk1)
CN101190330A (zh) 2006-11-30 2008-06-04 深圳市鼎兴生物医药技术开发有限公司 胆碱酯酶在拮抗速激肽药物中的应用
BRPI0807972A2 (pt) 2007-01-24 2014-06-10 Glaxo Group Ltd Composições farmacêuticas compreendendo 3,5-diamino-6-(2,3-diclofenil)-l,2,4-triazina ou r(-)-2,4-diamino-5-(2,3-diclorofenil)-6-fluorometilpirim idina e uma nk1
WO2010081851A1 (en) 2009-01-14 2010-07-22 Genoscience Pharma Piperidin-4-ylpiperazine compounds for the treatment of hcv infection
CN101913076B (zh) * 2010-06-23 2012-09-05 中国科学院自动化研究所 基于工业机器人的活塞、活塞销和连杆装配方法及装置
GB201106817D0 (en) 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compound
GB201218864D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
GB201218862D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
GB201218850D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
US9980973B2 (en) 2012-10-19 2018-05-29 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
WO2014124222A1 (en) 2013-02-08 2014-08-14 General Mills, Inc. Reduced sodium food products
CN109336883B (zh) 2013-12-20 2022-06-14 阿斯特克斯治疗有限公司 双环杂环化合物及其治疗用途
WO2017118584A1 (en) * 2016-01-08 2017-07-13 Nerre Therapeutics Limited Orvepitant for the treatment of chronic cough

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2676055B1 (fr) * 1991-05-03 1993-09-03 Sanofi Elf Composes polycycliques amines et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant.
MY110227A (en) * 1991-08-12 1998-03-31 Ciba Geigy Ag 1-acylpiperindine compounds.
CN1042335C (zh) * 1993-01-03 1999-03-03 诺瓦提斯公司 1－酰基哌啶化合物、其制备方法、药物组合物及用途
DE59307210D1 (de) * 1993-05-12 1997-10-02 Heumann Pharma Gmbh & Co Stabile und kristalline Form von Bezafibrat
GB9310066D0 (en) * 1993-05-17 1993-06-30 Zeneca Ltd Alkyl substituted heterocycles
WO1995011895A1 (en) * 1993-10-26 1995-05-04 Ciba-Geigy Ag N-benzoyl-4-oxy/thio-2-substituted piperidines as substance-p receptor antagonists
IL111730A (en) * 1993-11-29 1998-12-06 Fujisawa Pharmaceutical Co Piperazine derivatives, processes for their preparation and pharmaceutical preparations containing them
US5814636A (en) * 1994-07-15 1998-09-29 Meiji Seika Kabushiki Kaisha Compounds with platelet aggregation inhibitor activity
HUT77318A (hu) * 1994-09-30 1998-03-30 Novartis Ag. 1-Acil-4-/(alifás amino)-piperidin/-származékok, e vegyületeket tartalmazó gyógyszerkészítmények, eljárás előállításukra és alkalmazásuk
NZ321575A (en) * 1995-10-30 1999-05-28 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4- substituted piperazine derivatives

Also Published As

Publication number Publication date
TW460473B (en) 2001-10-21
NO310232B1 (no) 2001-06-11
DK0862566T3 (da) 2000-06-13
TR199800756T2 (xx) 1998-07-21
ATE188691T1 (de) 2000-01-15
EP0862566B1 (en) 2000-01-12
NO981534D0 (no) 1998-04-03
KR100407067B1 (ko) 2004-06-04
PT862566E (pt) 2000-06-30
CN100415716C (zh) 2008-09-03
MX9803407A (es) 1998-09-30
USRE37886E1 (en) 2002-10-15
KR19990064178A (ko) 1999-07-26
AU7493296A (en) 1997-05-22
PL327406A1 (en) 1998-12-07
EA000909B1 (ru) 2000-06-26
DE69606196D1 (de) 2000-02-17
EP0862566A1 (en) 1998-09-09
HRP960507A2 (en) 1998-02-28
AU704155B2 (en) 1999-04-15
CN1205699A (zh) 1999-01-20
CN1117744C (zh) 2003-08-13
EA199800404A1 (ru) 1998-10-29
WO1997016440A1 (en) 1997-05-09
CN1438220A (zh) 2003-08-27
CA2234096A1 (en) 1997-05-09
US6197772B1 (en) 2001-03-06
MY116575A (en) 2004-02-28
HRP960507B1 (en) 2001-08-31
PL185029B1 (pl) 2003-02-28
CY2177B1 (en) 2002-08-23
SI0862566T1 (en) 2000-04-30
HUP9802985A2 (hu) 1999-10-28
JP3073238B2 (ja) 2000-08-07
BR9611184A (pt) 1999-03-30
GR3033154T3 (en) 2000-08-31
HUP9802985A3 (en) 2002-10-28
JPH11514634A (ja) 1999-12-14
NZ321575A (en) 1999-05-28
CA2234096C (en) 2005-06-14
IL123962A (en) 2001-01-11
ZA969090B (en) 1998-04-29
AR004698A1 (es) 1999-03-10
HU227341B1 (en) 2011-04-28
BR9611184B8 (pt) 2015-02-18
NO981534L (no) 1998-06-24
US6521621B1 (en) 2003-02-18
CZ132298A3 (cs) 1998-09-16
DE69606196T2 (de) 2000-09-21
CZ291794B6 (cs) 2003-05-14

Similar Documents

Publication Publication Date Title
ES2143238T3 (es) Derivados de 1-(piperidinil disustituido en posiciones 1,2)-piperazinas sustituidas en posicion 4.
ES2164939T3 (es) Derivados de 1-(1,2-piperidinil disustituido)-4-piperidina sustituida como antagonistas de receptores de taquicinina.
ES2119472T3 (es) Derivados aminoheterociclicos como agentes antitromboticos o anticoagulantes.
CO4930259A1 (es) Derivados 6,6-heterobiciclicos sustituidos y composiciones farmaceuticas que los contienen
AR003455A1 (es) Derivados tetraciclicos, su uso en la preparacion de un medicamento, un metodo de tratamiento, una composicion farmaceutica y procesos para lapreparacion de una composicion farmaceutica y para preparar los compuestos.
AR009413A1 (es) Un compuesto, el cual es un derivado de distamicina benzoheterociclico, su utilizacion, un procedimiento para producirlo y una composicionfarmaceutica que lo comprende
ATE267200T1 (de) Bicyclische kinase inhibitoren
AR015103A1 (es) Compuestos derivados de 6,6-heterobiciclicos sustituidos y composiciones que los contienen e intermediarios
DOP2010000046A (es) Compuestos de biciclolactama sustituida
ES2162933T3 (es) Compuestos utiles como agentes antiproliferativos e inhibidores del enzima glicinamida ribonucleotido formilo transferasa (garft).
ES2059335T3 (es) Derivados de pirido(3,2,1-ij)-1,3,4-benzoxadiazina, procedimiento para su obtencion, preparados farmaceuticos correspondientes y productos intermedios utilizables en el procedimiento.
NO20025641D0 (no) Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister
ES2058265T3 (es) Piperidinas antagonistas de opiaceos.
AR029942A1 (es) Compuestos derivados de 1,3-dihidro-2h-indol-2-ona, su utilizacion, procedimiento para su preparacion y composiciones farmaceuticas que los comprenden, medicamentos constituidos por dichos compuestos y compuestos intermediarios
AR007108A1 (es) Agentes antitumorales y antivirales alquilantes, procedimiento para su preparacion, utilizacion de los mismos para la fabricacion de un medicamento y composicion farmaceutica que contiene a dichos agentes.
ES2059804T3 (es) Procedimiento de preparacion de eteres de oxima de propenona.
AR027539A1 (es) Nuevos derivados de 1,3-dihidro-2h-indol-2-ona, un procedimiento para su preparacion y las composiciones farmaceuticas que los contienen
NO20025640D0 (no) Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister
ES2152682T3 (es) Derivados de indolina utiles como antagonistas del receptor 5ht-2c.
MX9306394A (es) Derivados de benzofurano, proceso para su preparacion y composicion farmaceutica que los contiene
ES2112483T3 (es) 4-aril-4-hidroxi-tetrahidropiranos y 3-aril-3-hidroxi-tetrahidrofuranos como inhibidores de 5-lipoxigenasa.
ES2143630T3 (es) Derivados azabicicloalquilos de imidazo(1,5-a)indol-3-ona utilizados como antagonistas de 5ht3.
ATE246174T1 (de) Tosylprolin-derivate als thymidylat-synthase inhibitoren
ES2057415T3 (es) Derivados biciclicos.
ES2183500T3 (es) Nuevos compuestos y composiciones farmaceuticas que los contienen.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 862566

Country of ref document: ES